A Pharmacodynamic Study of CN-218, a Novel Antiplatelet and Antithrombotic Agent Primarily Targeting the P2Y 12 Receptor

ConclusionCN-218 may be a promising antithrombotic agent, with potent antiplatelet and significant anticoagulant activity, as well as a lower risk of bleeding compared to clopidogrel and prasugrel.

http://link.springer.com/10.1007/s10557-019-06930-9

Source: Cardiovascular Drugs and Therapy - February 14, 2020 Category: Cardiology Source Type: research